当前位置: 首页 >> 检索结果
7041. Idiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene.
作者: Yushiro Endo.;Tomohiro Koga.;Hiroki Otaki.;Daisuke Sasaki.;Remi Sumiyoshi.;Kaori Furukawa.;Yoshimasa Tanaka.;Yanagihara Katsunori.;Atsushi Kawakami.
来源: Rheumatology (Oxford). 2021年60卷1期445-450页
While the aetiology of idiopathic multicentric Castleman disease (iMCD) remains unclear, the involvement of autoinflammatory mechanisms has been suggested. Herein we report a Japanese patient with iMCD with a novel heterozygous Ile729Met mutation in exon 10 of the Mediterranean fever (MEFV) gene.
7042. High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis.
作者: Lauren V Host.;Corrado Campochiaro.;Ana Afonso.;Svetlana I Nihtyanova.;Christopher P Denton.;Voon H Ong.
来源: Rheumatology (Oxford). 2021年60卷2期849-854页
To investigate the association between proton pump inhibitor (PPI) use and the presence and severity of calcinosis in SSc.
7043. LncRNA-H19 silencing suppresses synoviocytes proliferation and attenuates collagen-induced arthritis progression by modulating miR-124a.
作者: Xiaohong Fu.;Guojing Song.;Rongrong Ni.;Han Liu.;Zhizhen Xu.;Dinglin Zhang.;Fengtian He.;Gang Huang.
来源: Rheumatology (Oxford). 2021年60卷1期430-440页
Long non-coding RNA H19 (lncRNA-H19) is highly expressed in fibroblast-like synoviocytes (FLS) from patients with RA. The present study aimed to clarify the pathological significance and regulatory mechanisms of lncRNA-H19 in FLS.
7044. External validation of the EULAR/ACR idiopathic inflammatory myopathies classification criteria with a Japanese paediatric cohort.
作者: Kazuko Yamazaki.;Akiko Ohta.;Shinji Akioka.;Yuichi Yamasaki.;Asami Ohara.;Haruna Nakaseko.;Kenichi Nishimura.;Norimoto Kobayashi.;Yutaka Nishida.;Satoshi Sato.;Shunichiro Takezaki.;Takayuki Kishi.;Motomu Hashimoto.;Ichiro Kobayashi.;Masaaki Mori.; .
来源: Rheumatology (Oxford). 2021年60卷2期802-808页
To assess the performance of the EULAR/ACR idiopathic inflammatory myopathies (IIMs) classification criteria to classify juvenile IIMs (JIIMs) in an Asian paediatric population.
7045. Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk.
作者: Judith Wienke.;Jorre S Mertens.;Samuel Garcia.;Johan Lim.;Camiel A Wijngaarde.;Joo Guan Yeo.;Alain Meyer.;Lucas L van den Hoogen.;Janneke Tekstra.;Jessica E Hoogendijk.;Henny G Otten.;Ruth D E Fritsch-Stork.;Wilco de Jager.;Marieke M B Seyger.;Rogier M Thurlings.;Elke M G J de Jong.;Anneke J van der Kooi.;W Ludo van der Pol.; .;Thaschawee Arkachaisri.;Timothy R D J Radstake.;Annet van Royen-Kerkhof.;Femke van Wijk.
来源: Rheumatology (Oxford). 2021年60卷2期785-801页
Vasculopathy is an important hallmark of systemic chronic inflammatory connective tissue diseases (CICTD) and is associated with increased cardiovascular risk. We investigated disease-specific biomarker profiles associated with endothelial dysfunction, angiogenic homeostasis and (tissue) inflammation, and their relation to disease activity in rare CICTD.
7046. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.
作者: Delphine S Courvoisier.;Katarina Chatzidionysiou.;Denis Mongin.;Kim Lauper.;Xavier Mariette.;Jacques Morel.;Jacques-Eric Gottenberg.;Sytske Anne Bergstra.;Manuel Pombo Suarez.;Catalin Codreanu.;Tore K Kvien.;Maria Jose Santos.;Karel Pavelka.;Merete L Hetland.;Johan Askling.;Carl Turesson.;Satoshi Kubo.;Yoshiya Tanaka.;Florenzo Iannone.;Denis Choquette.;Dan C Nordström.;Ziga Rotar.;Galina Lukina.;Cem Gabay.;Ronald Van Vollenhoven.;Axel Finckh.
来源: Rheumatology (Oxford). 2021年60卷2期820-828页
RF and ACPA are used as diagnostic tools and their presence has been associated with clinical response to some biologic DMARDs (bDMARDs) in RA. This study compared the impact of seropositivity on drug discontinuation and effectiveness of bDMARDs in patients with RA, using head-to-head comparisons in a real-world setting.
7047. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
作者: Karin Hellgren.;Daniela Di Giuseppe.;Karin E Smedby.;Christer Sundström.;Johan Askling.;Eva Baecklund.; .
来源: Rheumatology (Oxford). 2021年60卷2期809-819页
To estimate the association between biological DMARDs (bDMARDs; overall and by drug) as used in RA and the risk of malignant lymphomas including subtypes.
7048. Splicing factor SRSF1 limits IFN-γ production via RhoH and ameliorates experimental nephritis.
作者: Takayuki Katsuyama.;Hao Li.;Suzanne M Krishfield.;Vasileios C Kyttaris.;Vaishali R Moulton.
来源: Rheumatology (Oxford). 2021年60卷1期420-429页
CD4 T helper 1 (Th1) cells producing IFN-γ contribute to inflammatory responses in the pathogenesis of SLE and lupus nephritis. Moreover, elevated serum type II IFN levels precede the appearance of type I IFNs and autoantibodies in patient years before clinical diagnosis. However, the molecules and mechanisms that control this inflammatory response in SLE remain unclear. Serine/arginine-rich splicing factor 1 (SRSF1) is decreased in T cells from SLE patients, and restrains T cell hyperactivity and systemic autoimmunity. Our objective here was to evaluate the role of SRSF1 in IFN-γ production, Th1 differentiation and experimental nephritis.
7049. First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine.
作者: Marleen E Jacobs.;Juliëtte N Pouw.;Paco Welsing.;Timothy R D J Radstake.;Emmerik F A Leijten.
来源: Rheumatology (Oxford). 2021年60卷2期780-784页
Conventional synthetic DMARDs (csDMARDs) are the first-line treatment for PsA, but there is conflicting data regarding their efficacy and scarce reports describing the duration of use (drug retention) of csDMARD in this population. Their position in treatment recommendations is a matter of growing debate due to the availability of alternative treatment options with higher levels of evidence. We aimed to study drug retention and predictors for drug retention among PsA patients receiving first-line csDMARD monotherapy.
7051. Comparison of three different definitions of low disease activity in patients with systemic lupus erythematosus and their prognostic utilities.
作者: Ji-Hyoun Kang.;Min-Ho Shin.;Sung-Eun Choi.;Haimuzi Xu.;Dong-Jin Park.;Shin-Seok Lee.
来源: Rheumatology (Oxford). 2021年60卷2期762-766页
Three definitions of low-level disease activity in patients with SLE have been proposed by different groups. These include minimal disease activity (MDA), low disease activity (LDA) and the lupus low disease activity state (LLDAS). We investigated the performance of these definitions in SLE patients.
7052. Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients.
作者: Fausto Salaffi.;Marco Di Carlo.;Laura Bazzichi.;Fabiola Atzeni.;Marcello Govoni.;Giovanni Biasi.;Manuela Di Franco.;Flavio Mozzani.;Elisa Gremese.;Lorenzo Dagna.;Alberto Batticciotto.;Fabio Fischetti.;Roberto Giacomelli.;Serena Guiducci.;Giuliana Guggino.;Mario Bentivegna.;Roberto Gerli.;Carlo Salvarani.;Gianluigi Bajocchi.;Marco Ghini.;Florenzo Iannone.;Valeria Giorgi.;Sonia Farah.;Mariateresa Cirillo.;Sara Bonazza.;Stefano Barbagli.;Chiara Gioia.;Daniele Santilli.;Annunziata Capacci.;Giulio Cavalli.;Francesco Carubbi.;Francesca Nacci.;Ilenia Riccucci.;Luigi Sinigaglia.;Maurizio Masullo.;Bianca Maria Polizzi.;Maurizio Cutolo.;Piercarlo Sarzi-Puttini.
来源: Rheumatology (Oxford). 2021年60卷2期728-736页
To establish optimal cut-off values for the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromialgia Assessment Scale (FAS 2019mod), and the Polysymptomatic Distress Scale (PDS) in order to distinguish five levels of FM disease severity.
7054. Broad proteomic screen reveals shared serum proteomic signature in patients with psoriatic arthritis and psoriasis without arthritis.
作者: Emmerik Leijten.;Weiyang Tao.;Juliette Pouw.;Tessa van Kempen.;Michel Olde Nordkamp.;Deepak Balak.;J Tekstra.;Ernesto Muñoz-Elías.;Samuel DePrimo.;Julia Drylewicz.;Aridaman Pandit.;Marianne Boes.;Timothy Radstake.
来源: Rheumatology (Oxford). 2021年60卷2期751-761页
To identify novel serum proteins involved in the pathogenesis of PsA as compared with healthy controls, psoriasis (Pso) and AS, and to explore which proteins best correlated to major clinical features of the disease.
7055. Which factors predict discordance between a patient and physician on a gout flare?
作者: Aprajita Jagpal.;Elizabeth J Rahn.;Amy S Mudano.;Nicola Dalbeth.;William Taylor.;Kenneth G Saag.;Jasvinder A Singh.;Lorenzo Cavagna.;Till Uhlig.;Fernando Perez-Ruiz.;Geraldine McCarthy.;Martijn Gerritsen.;Lisa Stamp.;Janitzia Vazquez Mellado.;Chingtsai Lin.;Ana Beatriz Vargas-Santos.;Worawit Louthrenoo.;Tuhina Neogi.;Yi-Hsing Chen.;Geraldo da Rocha Castelar-Pinheiro.;Angelo Gaffo.
来源: Rheumatology (Oxford). 2021年60卷2期773-779页
To investigate the factors associated with discordance between patient and physician on the presence of a gout flare.
7056. Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis.
作者: Kelvin Y C Yu.;Susan Yung.;Mel K M Chau.;Colin S O Tang.;Desmond Y H Yap.;Alexander H N Tang.;Shirley K Y Ying.;Cheuk Kwong Lee.;Tak Mao Chan.
来源: Rheumatology (Oxford). 2021年60卷2期737-750页
We investigated circulating syndecan-1, HA and thrombomodulin levels in patients with biopsy-proven Class III/IV ± V LN and their clinico-pathological associations. Patients with non-renal SLE or non-lupus chronic kidney disease, and healthy subjects served as controls.
7057. Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study.
作者: Yanying Liu.;Lijuan Zhu.;Zhenfan Wang.;Qiaozhu Zeng.;Fei Yang.;Jingyuan Gao.;Ziqiao Wang.;Kunkun Wang.;Limin Ren.;Yanyan Zhang.;Shanshan Zhang.;Yi Wang.;Danhua Shen.;Changsheng Xia.;Guangyan Yu.;Zhanguo Li.
来源: Rheumatology (Oxford). 2021年60卷2期767-772页
IgG4-related disease (IgG4-RD) is recently recognized as a fibro-inflammatory condition featured by tumefactive lesions in multiple organs, and the retroperitoneum is one of the common involved sites. We undertook this study to compare detailed demographic, clinical and laboratory characteristics of IgG4-RD patients with retroperitoneum lesion (IgG4-RD RPF+) and retroperitoneum free IgG4-RD (IgG4-RD RPF-) in a large cohort.
7058. Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI).
作者: Janet E Pope.;Emmanouil Rampakakis.;Mohammad Movahedi.;Angela Cesta.;John S Sampalis.;Claire Bombardier.; .
来源: Rheumatology (Oxford). 2021年60卷2期717-727页
RA patients are often not in remission due to patient global assessment of disease activity (PtGA) included in disease activity indices. The aim was to assess the lag of patient-reported outcomes (PROs) after remission measured by clinical disease activity index (CDAI) or swollen joint count (SJC28).
7059. Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies.
作者: Ryan M Close.;Laura M Close.;Patrick Galdun.;Stefanie Gerstberger.;Matthew Rydberg.;Lisa Christopher-Stine.
来源: Rheumatology (Oxford). 2021年60卷2期692-698页
Statin-associated autoimmune myopathy is a rare condition associated with the formation of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Underlying environmental and genetic risk factors remain poorly understood. American Indians have high rates of cardiovascular disease and associated co-morbidities that require lipid-lowering therapies. We observed this autoimmune myopathy in a series of American Indian statin users in rural Arizona.
7060. The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice.
作者: Jean W Liew.;Suleman Bhana.;Wendy Costello.;Jonathan S Hausmann.;Pedro M Machado.;Philip C Robinson.;Emily Sirotich.;Paul Sufka.;Zachary S Wallace.;Jinoos Yazdany.;Rebecca Grainger.; .
来源: Rheumatology (Oxford). 2021年60卷1期353-358页
As the coronavirus disease 2019 pandemic developed there was a paucity of data relevant to people living with rheumatic disease. This led to the development of a global, online registry to meet these information needs. This manuscript provides a detailed description of the coronavirus disease 2019 Global Rheumatology Alliance registry development, governance structure, and data collection, and insights into new ways of rapidly establishing global research collaborations to meet urgent research needs.
|